ScholarlyArticle · 2026
First-Line Nivolumab Plus Ipilimumab in Inoperable Epithelioid Malignant Pleural Mesothelioma: Real-World Experience From an Indian Tertiary Care Center
5 sections · about 10 minutes · source text with editorial apparatus kept separate